Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats.
Chronic administration of anorexigenic substances to experimental animals by injections or continuous infusion typically produces no effect or a transient reduction in daily food intake and body weight. Our aim was to identify an intermittent dosing strategy for intraperitoneal infusion of salmon calcitonin (sCT), a homolog of amylin that produces a sustained 25-35% reduction in daily food intake and adiposity in diet-induced obese rats. Rats (649 +/- 10 g body wt, 27 +/- 1% body fat), with intraperitoneal catheters tethered to infusion swivels, had free access to a 45% fat diet. Food intake, body weight, and adiposity during the 7-wk test period were relatively stable in the vehicle-treated rats (n = 16). None of 10 sCT dosing regimens administered in succession to a second group of rats (n = 18) produced a sustained 25-35% reduction in daily food intake for >5 days, although body weight and adiposity were reduced by 9% (587 +/- 12 vs. 651 +/- 14 g) and 22% (20.6 +/- 1.2 vs. 26.5 +/- 1.1%), respectively, across the 7-wk period. The declining inhibitory effect of sCT on daily food intake with the 6-h interinfusion interval appeared to be due in part to an increase in food intake between infusions. The declining inhibitory effect of sCT on daily food intake with the 2- to 3-h interinfusion interval suggested possible receptor downregulation and tolerance to frequent sCT administration; however, food intake increased dramatically when sCT was discontinued for 1 day after apparent loss of treatment efficacy. Together, these results demonstrate the activation of a potent homeostatic response to increase food intake when sCT reduces food intake and energy reserves in diet-induced obese rats.
Chelikani
Prasanth K
PK
Dept. of Veterans Affairs-Nebraska Western Iowa Health Care System, Creighton University, Omaha, NE 68105, USA.
Haver
Alvin C
AC
Reidelberger
Roger D
RD
D050154:Adiposity / Q000187:drug effects*; D000682:Amyloid / Q000378:metabolism; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002116:Calcitonin / Q000008:administration & dosage / Q000494:pharmacology*; D004032:Diet; D004435:Eating / Q000187:drug effects*; D007263:Infusions, Parenteral; D058228:Islet Amyloid Polypeptide; D008297:Male; D009765:Obesity / Q000188:drug therapy* / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley
D000682:Amyloid; D058228:Islet Amyloid Polypeptide; C028815:salmon calcitonin; D002116:Calcitonin